MannKind Corporation
(Public, NASDAQ:MNKD) Watch this stockFind more results for
MNKD
Advertisement
Events
Nov 17, 2009
Lazard Capital Healthcare Conference
Nov 5, 2009
Imperial Capital Global Opportunities Conference
Nov 2, 2009
Q3 2009 Earnings Conference Call -
Nov 2, 2009
Q3 2009 Earnings Release
Oct 6, 2009
JMP Securities Healthcare Focus Conference
Sep 22, 2009
UBS Global Life Sciences Conference
Sep 15, 2009
Morgan Stanley Global Healthcare Conference -
Sep 10, 2009
Rodman & Renshaw Annual Global Investment Conference
|
More events from AOL Finance »
|
Key stats and ratios
| Q3 (Sep '09) | 2008 | |
| Net profit margin | - | -1515195.00% |
| Operating margin | - | -1528825.00% |
| EBITD margin | - | -1469825.00% |
| Return on average assets | -65.75% | -73.38% |
| Return on average equity | - | -134.43% |
| Employees | 580 | - |
Address
Website links
Company website:
http://www.mannkindcorp.com/
http://www.mannkindcorp.com/
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance
Annual Report (PDF) - AnnualReports.com
MannKind Corporation discussed on blogs
Ranking All U.S. Stocks by Weekly Performance - NASD100.com ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- 9 hours ago
Ranking 1500+ Small Cap Stocks by Year-to-Date Performance ...
- Investor's Resources
- NASD100.com - Daily Stock Rankings
- Nov 20, 2009
MannKind Corporation discussions
View all discussions »Description
MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. Its lead product candidate, AFRESA, is an ultra rapid-acting insulin that has completed Phase III clinical trials evaluating its safety and efficacy in the treatment of diabetes. AFRESA consists of the Company’s Technosphere particles, onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled deep into the lung using the Company’s AFRESA inhaler.
Officers and directors
| Alfred E. Mann | Chairman of the Board, Chief Executive Officer | |
| Hakan S. Edstrom | President, Chief Operating Officer, Director | |
| Matthew J. Pfeffer | Chief Financial Officer, Corporate Vice President | |
| Juergen A. Martens Ph.D. | Corporate Vice President - Operations, Chief Technology Officer | |
| Peter C. Richardson | Corporate Vice President, Chief Scientific Officer | |
| David Thomson Ph.D.,J.D. | Corporate Vice President, General Counsel and Corporate Secretary | |
| Diane M. Palumbo | Corporate Vice President - Human Resources | |
| Ronald Consiglio | Director | |
| Michael Friedman M.D. | Director | |
| Kent Kresa | Director |